Dutch biotech In­travacc seeks to bol­ster Nether­lands vac­cine man­u­fac­tur­ing abil­i­ties with new plants

The pan­dem­ic has giv­en a huge edge to any coun­try that can pro­duce vac­cine in its bor­ders. Now one vac­cine biotech is look­ing to make sure their coun­try has that edge for any fu­ture pan­dem­ic.

Ar­gu­ing Covid-19 ex­posed the Nether­lands’ “vul­ner­a­bil­i­ty,” Dutch vac­cines com­pa­ny In­travacc re­cent­ly an­nounced that its new “mod­ern pi­lot pro­duc­tion plant” will soon be func­tion­al and that it’s spear­head­ing a con­glom­er­ate de­sign­ing a mul­ti­pur­pose vac­cine pro­duc­tion plant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.